Evidence map›Paper›PMID 26903376›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2016

Argonaute 2-dependent Regulation of Gene Expression by Single-stranded miRNA Mimics.

Masayuki Matsui, Thazha P Prakash, David R Corey

Open access · hybridAbstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 68 citations in OpenAlex.

  1. Are RNA Therapies a Solid Foundation or a Frontier Yet to Be Conquered?International journal of molecular sciences · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Non-Coding RNA-Targeted Therapy: A State-of-the-Art Review.International journal of molecular sciences · 2024
    Review
  8. Review
  9. The Roles of microRNAs in the Cardiovascular System.International journal of molecular sciences · 2023
    Review
  10. Article
  11. Article
  12. MicroRNAs as therapeutic targets in cardiovascular disease.The Journal of clinical investigation · 2022
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Masayuki MatsuiDepartment of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Thazha P PrakashDepartment of Medicinal Chemistry, Ionis Pharmaceuticals, Carlsbad, California, USA.
David R CoreyDepartment of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
The University of Texas Southwestern Medical Center · USIonis Pharmaceuticals (United States) · US

Funding

Recognition of Chromosomal DNA by Peptide Nucleic AcidsR01GM073042 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI COREY, DAVID R · 2005 to 2016
$3.5M
Mechanism of RNA-Mediated Control of Transcription or SplicingR01GM106151 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI COREY, DAVID R · 2014 to 2016
$859k
NIGMS NIH HHS R01 GM073042NIGMS NIH HHS R01 GM106151
6 · The paper itself

Abstract

MicroRNAs (miRNAs) are small noncoding transcripts that regulate gene expression. Aberrant expression of miRNAs can affect development of cancer and other diseases. Synthetic miRNA mimics can modulate gene expression and offer an approach to therapy. Inside cells, mature miRNAs are produced as double-stranded RNAs and miRNA mimics typically retain both strands. This need for two strands has the potential to complicate drug development. Recently, synthetic chemically modified single-stranded silencing RNAs (ss-siRNA) have been shown to function through the RNAi pathway to induce gene silencing in cell culture and animals. Here, we test the hypothesis that single-stranded miRNA (ss-miRNA) can also mimic the function of miRNAs. We show that ss-miRNAs can act as miRNA mimics to silence the expression of target genes. Gene silencing requires expression of argonaute 2 (AGO2) protein and involves recruitment of AGO2 to the target transcripts. Chemically modified ss-miRNAs function effectively inside cells through endogenous RNAi pathways and broaden the options for miRNA-based oligonucleotide drug development.

Indexed as

A549 CellsAnimalsArgonaute ProteinsBiomimetic MaterialsGene Expression Regulation, NeoplasticGene SilencingHeLa CellsHep G2 CellsHumansMicroRNAsMolecular MimicryArgonaute ProteinsMicroRNAs

Identifiers

PMID26903376
PMCPMC4881773
OpenAlexW2329920508

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.